Matches in Wikidata for { <http://www.wikidata.org/entity/Q93170964> ?p ?o ?g. }
Showing items 1 to 36 of
36
with 100 items per page.
- Q93170964 description "2019 ഏപ്രില് 17 നു പ്രസിദ്ധീകരിച്ച ശാസ്ത്ര ലേഖനം" @default.
- Q93170964 description "artículu científicu espublizáu n'abril de 2019" @default.
- Q93170964 description "scientific article published on 17 April 2019" @default.
- Q93170964 description "wetenschappelijk artikel" @default.
- Q93170964 description "наукова стаття, опублікована 17 квітня 2019" @default.
- Q93170964 name "BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha" @default.
- Q93170964 name "BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha" @default.
- Q93170964 type Item @default.
- Q93170964 label "BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha" @default.
- Q93170964 label "BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha" @default.
- Q93170964 prefLabel "BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha" @default.
- Q93170964 prefLabel "BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha" @default.
- Q93170964 P1433 Q93170964-4AAF2B24-74EC-4056-904B-9F72CBA4872F @default.
- Q93170964 P1476 Q93170964-62C9FFAE-CE45-4B8A-93D6-5D5B4791EB95 @default.
- Q93170964 P2093 Q93170964-55D4FFCE-4817-4DF2-950D-2DAD62F4B47F @default.
- Q93170964 P2093 Q93170964-71FD19E1-D29E-48F5-B54E-4C38CACD14BF @default.
- Q93170964 P304 Q93170964-89EC2362-C4E3-4038-B3A0-D082BACC4401 @default.
- Q93170964 P31 Q93170964-32341693-FB2B-4651-8157-1D57DA6D2AA5 @default.
- Q93170964 P356 Q93170964-CB9AA71D-77F4-467D-AAA0-3576578759BB @default.
- Q93170964 P433 Q93170964-735A60CB-9526-42EB-88C8-711365A4717C @default.
- Q93170964 P478 Q93170964-D73A1C91-237E-475A-9C4B-C3D93C3E6677 @default.
- Q93170964 P577 Q93170964-EDA1121B-6CB7-467B-AECF-4B80C530E5D2 @default.
- Q93170964 P698 Q93170964-5D34D824-283B-4414-A8FD-3AEE2FFC7E1A @default.
- Q93170964 P356 S00280-019-03842-1 @default.
- Q93170964 P698 30997532 @default.
- Q93170964 P1433 Q326137 @default.
- Q93170964 P1476 "BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha" @default.
- Q93170964 P2093 "Faruk Tas" @default.
- Q93170964 P2093 "Kayhan Erturk" @default.
- Q93170964 P304 "521-526" @default.
- Q93170964 P31 Q13442814 @default.
- Q93170964 P356 "10.1007/S00280-019-03842-1" @default.
- Q93170964 P433 "3" @default.
- Q93170964 P478 "84" @default.
- Q93170964 P577 "2019-04-17T00:00:00Z" @default.
- Q93170964 P698 "30997532" @default.